Telegram-
Loading indices

KOSPI · 003000

BukwangPharm

Market cap₩389B
PER42.88×
PBR1.16×
Foreign ownership6.89%

Pension summary

as of Oct 19
streakNone
5D+₩30M
20D+₩40M
60D-₩100M
Foreign 20D-₩930M
Inst. 20D+₩120M

Pension daily net buy

-

Cumulative net buying by investor

-
선택 기간의 net buy Total · ₩100M
DateClosePension fundsForeignInstitutionsRetail
10/193,970–₩0M₩0M₩0M
10/163,925–+₩550M+₩90M-₩640M
10/153,645+₩10M-₩340M-₩70M+₩420M
10/143,850+₩10M-₩160M+₩40M+₩120M
10/133,895+₩10M-₩150M-₩30M+₩180M
10/123,940+₩10M-₩320M-₩120M+₩440M
10/84,070–-₩60M-₩40M+₩90M
10/74,240–-₩980M+₩20M+₩960M
10/64,165–+₩40M+₩20M-₩50M
10/24,120–-₩40M-₩10M+₩40M

Discussion

Google-verified members · return since posting
0/300

  1. Loading

세력 매집

last 60 trading days · Oct 19
Foreign 60D−₩1.7B
Pension funds 60D−₩100M
세력 Avg. cost4,034
vs. cost Close-1.6%

Foreign+Pension funds Total 시총의 -0.5%, 60D price 폭 23%·Chg +5.9%. 세력 Avg. cost net buy한 날의 Avg 매수단가로 낸 est.치예요.

세력 매집 구간 All →

Financial score

#355 of KOSPI 500
46.6/100
  • Value7.4
  • Quality8.5
  • Growth7.5
  • Financials10
  • Risk13.2
소외
All stock scores →

ETF

ETFs holding it in their top 10 · recent changes

10/08 이후 큰 ETF 변화는 없어요

All ETF index changes →

Recent filings

DART
  1. Loading

Broker price targets

Recent 1Y

Recent reports

  1. 본업 Growth세 위에 RNA 플랫폼 재평가 기대Korea IR Council · 06/02
  2. CNS 혁신신약 분야를 선도하는 오픈 이노베이션의 강자NICE D&B · 12/06

Latest report per broker in the past year · Source: Naver Securities Research, Hankyung Consensus · Analyst names masked

Same sector

  1. Samsung Biologics
  2. Celltrion
  3. SAMSUNG EPIS HOLDINGS
  4. Yuhan
  5. SK Biopharm
  6. HanmiPharm

BukwangPharm summary

BukwangPharm (003000). Pension funds last 20 trading days +₩40M. Market cap ₩389B, PER 42.88×, PBR 1.16×. Pension flows are based on Korea Exchange investor statistics, for reference only.